Indication: Lung Cancer/ Breast Cancer

A Phase 1 Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses and treatment intensification of a vaccine-based immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for advanced non-small cell lung cancer and metastatic triple-negative breast cancer

Non-Small Cell Lung & Triple Neg Breast Cancer

Sub-indication: Advanced NSCLC or metastatic Triple Negative Breast Cancer

Line of Therapy: Multiple lines of therapy allowed. Resistant to standard therapy or no standard therapy available or refused by patient

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Pfizer

Learn more at ClinicalTrials.gov

Email for more information: CancerResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.